 |
 |
           |
|
Our Technology & IP What is Virotherapy? Virotherapy is the use of viruses to treat cancer. The first recognition of the potential of virotherapy dates back over a hundred years, when it was noted that some patients with terminal cancers went into remission after suffering a viral infection. Attempts were made then to treat cancer patients with viruses but the effects were inconsistent and generally of short duration. Progress in virology and an understanding of the mechanisms by which viruses can kill cancer cells, as well as the ability to ‘engineer’ viruses, are again leading to interest in oncolytic viruses as potential treatments for cancer. An oncolytic virus is a virus (either naturally occurring or genetically engineered) that will grow in a cancer cell and kill it. Once it enters a cancer cell, the virus replicates (reproduces), and when it kills the cancer cell, the virus spreads to other cancer cells. Intellectual Property Viralytics’s intellectual property is protected in the traditional fashion by patents that provide Viralytics the exclusive (and legally enforceable) right to commercially exploit that 'invention' for the life of the patent, which is typically 20 years. Viralytics is actively managing a suite of patents for both its wholly owned investments in virotherapy and dermatology. Viralytics has also obtained trademarks for its lead technology CAVATAK™ (virotherapy). This trademark uniquely identifies and distinguishes Viralytics’s technology from those manufactured or sold by others. |
|
|
|
||||||||
   
|
||||||||||||||
